ArticleCurrent drug targets2015
Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs.
Article in Current drug targets, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Intraorgan and targeted nanodelivery in organ transplantation of nonhuman primates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Kartogenin delivery systems for biomedical therapeutics and regenerative medicine.Drug delivery · 2023Review
- Nanoparticle-Based Interventions for Liver Transplantation.International journal of molecular sciences · 2023Review
- Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy.Clinical and translational medicine · 2019Review
- Exosome-like Nanovectors for Drug Delivery in Cancer.Current medicinal chemistry · 2019Review
- Trends towards Biomimicry in Theranostics.Nanomaterials (Basel, Switzerland) · 2018Review
- Inflammation and Cancer: In Medio Stat Nano.Current medicinal chemistry · 2018Review
- Chlorin e6 Functionalized Theranostic Multistage Nanovectors Transported by Stem Cells for Effective Photodynamic Therapy.ACS applied materials & interfaces · 2017Article
- Post-nano strategies for drug delivery: Multistage porous silicon microvectors.Journal of materials chemistry. B · 2017Article
- Enzyme-responsive multistage vector for drug delivery to tumor tissue.Pharmacological research · 2016Article
- A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.Pharmacological research · 2016Article
- The Emerging Role of Nanotechnology in Cell and Organ Transplantation.Transplantation · 2016Review
- Cell source determines the immunological impact of biomimetic nanoparticles.Biomaterials · 2016Article
- Multistage vector (MSV) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Nanoparticles have considerable potential for cancer imaging and therapy due to their small size and prolonged circulation. However, biological barriers can impede the delivery of a sufficient dose of a drug to the target site, thereby also resulting in the accumulation of toxic compounds within healthy tissues, and systemic toxicity. Multistage nanovectors (MSV) preferentially accumulate on inflamed endothelium, and can thus serve as carriers for drugs and nanoparticles. Herein, we describe the loading of free (i.e., melittin) and nano-encapsulated (i.e., doxorubicin-loaded micelles) drugs into MSV, and report the impact of surface charge and pore size on drug loading. For both drug formulations, negatively charged MSV (i.e., oxidized) with larger pores were shown to retain higher concentrations of payloads compared to positively charged (i.e., APTES-modified) MSV with small pores. Treatment of human umbilical vein endothelial cells (HUVEC) with melittin-loaded MSV (MEL@MSV) resulted in an 80% reduction in cell viability after 3 days. Furthermore, MEL@MSV conjugated with antivascular endothelial growth factor receptor 2 (VEGFR2) antibodies displayed preferential targeting and delivery of MEL to activated HUVEC expressing VEGFR2. Treatment of HUVEC and MCF7 cells with doxorubicin-loaded micelles (DOXNP@MSV) resulted in a 23% and 47% reduction in cell viability, respectively. Taken together, these results demonstrate increased loading of a payload in oxidized, large pore MSV, and effective delivery of free and nano-encapsulated drugs to endothelial and cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.